Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 4, 2025
Daily News
March 4, 2025
- Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
- 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
- Novartis Bags Global Rights to Kyorin’s MRGPRX2 Antagonist
March 4, 2025
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Blackstone to Buy 60% Stake in Japan CRO CMIC
March 4, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
- ASKA Ties Up with Philippines’ MedChoice in Thyroid Space
March 4, 2025
- Japan’s 1st CGP Assay for Blood Cancer Now Available: Otsuka
March 4, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…